Delcath Systems (NASDAQ:DCTH) Upgraded to Strong-Buy at Zacks Research

Delcath Systems (NASDAQ:DCTH) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Other analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Delcath Systems in a research note on Friday. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a report on Friday. Finally, BTIG Research raised their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.17.

Delcath Systems Trading Up 3.3%

DCTH stock opened at $17.22 on Monday. The company has a market capitalization of $597.53 million, a PE ratio of 1,723.72 and a beta of 0.52. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $17.42. The business’s fifty day moving average price is $12.61 and its 200 day moving average price is $10.97.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.The firm had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Research analysts predict that Delcath Systems will post -0.17 EPS for the current fiscal year.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in shares of Delcath Systems during the 2nd quarter worth about $26,000. Russell Investments Group Ltd. acquired a new stake in shares of Delcath Systems during the 3rd quarter worth about $29,000. Tower Research Capital LLC TRC acquired a new stake in shares of Delcath Systems during the 2nd quarter worth about $40,000. Legal & General Group Plc purchased a new stake in Delcath Systems during the second quarter worth approximately $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Delcath Systems during the second quarter worth approximately $151,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.